SGLT2 Adjunct in T1D
- Sponsor
- Ain Shams University
- Study ID
- NCT07591077
- Phase
- PHASE2/PHASE3
- Status
- Completed
Conditions
- Nephropathy, Diabetic
- Type 1 Diabetes
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 18 Years
- Healthy Volunteers
- Not accepted
Interventions
- Empagliflozin (EMPA) — DRUGempagliflozin oral once daily
- Placebo — OTHERplacebo
Study Details
Effect of Sodium-Glucose Cotransporter (SGLT) 2 Inhibitors on Diabetic Nephropathy Progression in Adolescents with Type 1 Diabetes Mellitus
Key Dates
- Start date
- Nov 20, 2024
- Status verified
- May 2026
- Primary completion
- Nov 20, 2025
- Completion
- Feb 20, 2026
Study Design
- Enrollment
- 86 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: EmpagliflozinEmpagliflozin 10 mg once daily
- Placebo Comparator: Placeboplacebo
Primary Outcome Measure
Nephropathy [ Time Frame: 6 months ]
Related Studies
- Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1EARLY_PHASE1 · Recruiting · Augusta University · Augusta, Georgia
- General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care DeliveryRecruiting · Sanford Health · Bemidji, Minnesota
- The T1D Exchange RegistryRecruiting · T1D Exchange, United States · Boston, Massachusetts
- Combined Antibody Screening for Celiac and Diabetes EvaluationEnrolling By Invitation · Pacific Northwest Research Institute · Seattle, Washington